Displaying 201 - 220 of 225
Mar09
FDA / FTC Workshop on a Competitive Marketplace for Biosimilars
-
The Federal Trade Commission in collaboration with the Food and Drug Administration held a public workshop, "FDA/FTC Workshop on a Competitive Marketplace for Biosimilars." The purpose of the public...
Marketers of Pain Relief Device Settle FTC False Advertising Complaint
Date
Under a settlement with the Federal Trade Commission, the marketers of an electrical nerve stimulation device called Quell have agreed to pay at least $4 million and stop making deceptive claims that...
FTC, FDA to Hold Workshop on Promoting Competition in Markets for Biologics
Date
On March 9, 2020, the Federal Trade Commission and the Food and Drug Administration will co-sponsor a public workshop on promoting competition in biologics markets. The workshop will be held at the...
FTC, FDA Sign Joint Statement Promoting Competition in Markets for Biologics
Date
Federal Trade Commission Chairman Joseph J. Simons today joined Food and Drug Administration Commissioner Stephen Hahn in signing a joint statement promoting competition in biologics markets....
Joint FDA-FTC Statement Regarding Collaboration to Advance Competition in the Biologic Marketplace
Date
Matter Number
V190003
FTC and FDA Warn Florida Company Marketing CBD Products about Claims Related to Treating Autism, ADHD, Parkinson’s, Alzheimer’s, and Other Medical Conditions
Date
The Federal Trade Commission announced a joint warning letter issued with the U.S. Food and Drug Administration (FDA) to Rooted Apothecary, LLC for selling products containing cannabidiol (CBD) online...
Reckitt Benckiser Group plc to Pay $50 Million to Consumers, Settling FTC Charges that the Company Illegally Maintained a Monopoly over the Opioid Addiction Treatment Suboxone
Date
Reckitt Benckiser Group plc has agreed to pay $50 million to settle Federal Trade Commission charges that it violated the antitrust laws through a deceptive scheme to thwart lower-priced generic...
FTC and FDA Send Warning Letters to Companies Selling Flavored E-liquids About Social Media Endorsements without Health Warnings
Date
The agencies sent the letters to firms that manufacture and market flavored e-liquid products. They cite postings by influencers on social media sites such as Facebook, Instagram, and Twitter that...
FTC Submits Comment on FDA Guidance Regarding Nonproprietary Naming of Biological Products
Date
The Federal Trade Commission staff has responded to the Food and Drug Administration’s request for comment on its updated industry guidance regarding nonproprietary naming of biological products. The...
FTC Joins FDA in Sending Warning Letters to Companies Advertising and Selling Products Containing Cannabidiol (CBD) Claiming to Treat Alzheimer’s, Cancer, and Other Diseases
Date
As part of its ongoing efforts to ensure that dietary supplements and other health-related products are advertised truthfully, and that efficacy claims made for such products are supported by...
FTC and FDA Send Warning Letters to Companies Selling Dietary Supplements Claiming to Treat Alzheimer’s Disease and Remediate or Cure Other Serious Illnesses Such as Parkinson’s, Heart Disease, and Cancer
Date
As part of its ongoing efforts to ensure that dietary supplements and other health-related products are advertised truthfully, and that efficacy claims made for such products are supported by...
FTC Submits Comment on FDA Guidance Aimed at Deterring Abuse of Citizen Petition Process
Date
The Federal Trade Commission has responded to the Food and Drug Administration’s request for comment on its revised draft guidance, which aims to deter pharmaceutical companies from abusing the...
FTC Submits Statement to HHS on Its Blueprint to Lower Drug Prices
Date
The Federal Trade Commission responded to the U.S. Department of Health and Human Services’ request for comment to its publication, Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. The...
FTC Amicus Brief Urges Federal District Court Not to Categorically Exempt Hatch Waxman Suits from Antitrust Scrutiny as Potential Sham Litigations
Date
The Federal Trade Commission has filed an amicus brief in Takeda Pharmaceutical Co. v Zydus Pharmaceuticals (USA) Inc., which is a patent infringement case pending before the U.S. District Court for...
FTC, FDA Take Action Against Companies Marketing E-liquids That Resemble Children’s Juice Boxes, Candies, and Cookies
Date
As part of ongoing efforts to protect youth from the dangers of nicotine and tobacco products, today the Federal Trade Commission (FTC) and the U.S. Food and Drug Administration (FDA) jointly issued...
FTC and FDA to Host Call-in Media Availability on Joint Actions Regarding Youth-Related Tobacco Issues
Date
The Federal Trade Commission (FTC) and U.S. Food and Drug Administration (FDA) will host a joint media call-in on Tuesday, May 1, 2018 at 11 a.m. to discuss actions regarding youth-related tobacco...
FTC, FDA Warn Companies about Marketing and Selling Opioid Cessation Products
Date
The Federal Trade Commission and the U.S. Food and Drug Administration (FDA) today posted warning letters to 11 marketers and distributors of opioid cessation products for illegally marketing products...
Prepared Statement of the Federal Trade Commission on "Antitrust Concerns and the FDA Approval Process,” Before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Judiciary Committee, United States House of Representatives
Date
By
Markus H. Meier, Acting Director, Bureau of Competition
Matter Number
P859900
File
Text of the Commission Testimony
(101.52 KB)
FTC Testifies before House Judiciary Committee’s Subcommittee on Regulatory Reform, Commercial and Antitrust Law about Antitrust Concerns and the FDA Approval Process
Date
In testimony presented to the U.S. House of Representatives’ Judiciary Committee Subcommittee on Regulatory Reform, Commerical and Antitrust Law, the Federal Trade Commission described its efforts to...
Displaying 201 - 220 of 225